Magnitude of Soluble ST2 as a Novel Biomarker for Acute Aortic Dissection

BACKGROUND—Misdiagnosis of acute aortic dissection (AAD) can lead to significant morbidity and death. Soluble ST2 (sST2) is a cardiovascular injury-related biomarker. The extent to which sST2 is elevated in AAD and whether sST2 can discriminate AAD from other causes of sudden-onset severe chest pain...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2018-01, Vol.137 (3), p.259-269
Main Authors: Wang, Yuan, Tan, Xin, Gao, Hai, Yuan, Hui, Hu, Rong, Jia, Lixin, Zhu, Junming, Sun, Lizhong, Zhang, Hongjia, Huang, Lianjun, Zhao, Dong, Gao, Pei, Du, Jie
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND—Misdiagnosis of acute aortic dissection (AAD) can lead to significant morbidity and death. Soluble ST2 (sST2) is a cardiovascular injury-related biomarker. The extent to which sST2 is elevated in AAD and whether sST2 can discriminate AAD from other causes of sudden-onset severe chest pain is unknown. METHODS—We measured plasma concentrations of sST2 (R&D systems assay) in 1360 patients, including 1027 participants in the retrospective discovery set and 333 patients with initial suspicion of AAD enrolled in the prospective validation cohort. Measures of discrimination for differentiating AAD from other causes of chest pain were calculated. RESULTS—In the acute phase, sST2 levels were higher in patients with AAD than those with either acute myocardial infarction (AMI) in the first case-control discovery set within 24h symptom onset or pulmonary embolism (PE) patients in the second discovery set (medians of 129.2 ng/mL vs. 14.7 with p
ISSN:0009-7322
1524-4539
DOI:10.1161/CIRCULATIONAHA.117.030469